Keck M
LVA Cardiac and Circulation Clinic, Bad Münster am Stein/Ebb, Germany.
J Cardiovasc Pharmacol. 1992;20 Suppl 6:S43-9.
The efficacy of nilvadipine and nitrendipine was compared in two double-blind, placebo-controlled trials. Patients had either mild-to-moderate hypertension (study 1) or moderate hypertension that was difficult to control (study 2). The criterion for efficacy was a mean drop in the median 24-h blood pressure profile after 10 days of medication compared with the placebo washout phase. Nilvadipine tended to be more efficacious than nitrendipine and had a significantly greater effect than placebo. The blood pressure reductions were more marked in the mild and moderate hypertension group than in patients with hypertension that was difficult to control. The hypotensive action of nilvadipine 16 mg lasted longer than that of nitrendipine 20 mg in all groups, especially in the group with difficult-to-control moderate hypertension. The response rate was somewhat higher in the nilvadipine group in both studies, particularly in patients with moderate hypertension that was difficult to control. Both substances were well tolerated, with fewer side effects noted for nilvadipine than for nitrendipine.
